Tecentriq
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.tecentriq.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Tecentriq
TECENTRIQ is a prescription medication designed for cancer immunotherapy, targeting several types of cancer including Non-Small Cell Lung Cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer (ES-SCLC), Hepatocellular Carcinoma (HCC), and Advanced Melanoma. It is intended for adults, particularly those whose cancer tests positive for specific biomarkers like PD-L1, and can be used in tandem with other treatments or as a standalone therapy. The medication may help enhance the immune system's ability to fight cancer, offering treatment options tailored to various stages and types of cancers. TECENTRIQ is primarily aimed at healthcare professionals in the United States who manage these specific oncology cases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tecentriq your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Tecentriq has recently received funding, and reach out quickly before it becomes old news!
Tecentriq, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Tecentriq recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Tecentriq
Product Launch: Get notified when Tecentriq launches new products
Click to see if Tecentriq had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Tecentriq is spiking on competitors!
Funding: Get notified immidiatlly once Tecentriq has new funding data
Recommended Actions
Reach out to Masked Content who joined Tecentriq as Masked Content
Find 2 more new buyers
Compare Similar Companies to Tecentriq
Compare insights from companies similar to Tecentriq, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tecentriq
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Tecentriq is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tecentriq is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tecentriq.
Tecentriq Tech Stack
A closer look at the technologies used by Tecentriq
See more technologies
Tecentriq News & Media
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard IV iGenentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the Phase III IMbrave050 study that show Tecentriq® (atezolizumab) plus Avastin® (bevacizumab) demonstrated a statistically significant improvement in recurrence-free survival (RFS) in people with hepatocellular carcinoma (HCC) at high risk of disease recurrence following liver resection or ablation with curative intent. “Four out of five people with HGenentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The TecGenentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-sma
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tecentriq
Sign Up For FreeTo access detailed company insights
TECENTRIQ is a prescription medication designed for cancer immunotherapy, targeting several types of cancer including Non-Small Cell Lung Cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer (ES-SCLC), Hepatocellular Carcinoma (HCC), and Advanced Melanoma. It is intended for adults, particularly those whose cancer tests positive for specific biom... Read More
